<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275376</url>
  </required_header>
  <id_info>
    <org_study_id>CF16263B</org_study_id>
    <nct_id>NCT03275376</nct_id>
  </id_info>
  <brief_title>Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,
      including the condition in Taiwan, and the management of HCC is an important challenge in
      public health. Target therapy with sorafenib is the standard of treatment for advanced HCC
      (vascular invasion or extrahepatic metastasis), but the patient survival time is still
      unsatisfactory. In recent years, growing evidences, including mechanism analysis, have
      suggested the anitneoplastic effects of statin, and a recent pooled analysis found that
      statin use may be associated with improved survival in patients with metastatic rencal cell
      carcinoma. However, a prospective clinical trial of statin sorafenib combination therapy in
      the treatment of advanced HCC is lacking.

      Aims:

        1. To prove statins improve the overall survival for patients who receive sorafenib therapy
           for advanced HCC by a prospective randomized controlled study.

        2. To prove statin can improve tumor responses and the progression free survival for
           patients who receive sorafenib therapy for advanced HCC by a prospective randomized
           controlled study.

      Methods:

      This randomized placebo-controlled study will prospectively enroll patients who receiving
      sorafenib therapy for advanced HCC in the Taichung Veterans General Hospital, and statin or
      placebo will be statin or placebo will be administered according to randomized allocations.
      Tumor responses, time to tumor progression, and survival time will be followed and recorded
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Three year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best tumor response</measure>
    <time_frame>Three year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Three year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Clinical Outcome Improvement</condition>
  <arm_group>
    <arm_group_label>Statin treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin or placebo will be administered according to randomized allocations.</description>
    <arm_group_label>Statin treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Atorvastatin or placebo will be administered according to randomized allocations.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients more than 40 years old

          2. HCCs diagnosed by AASLD image criteria or pathology

          3. HCCs in BCLC advanced stage, with portal vein thrombosis (VP3 or VP4) or extrahepatic
             metastasis

          4. Not suitable or failed to locoreginal treatments for HCC

          5. Child-Pugh score = or &lt; 6

          6. ECOG performance status (PST) 0-2

          7. Serum bilirubin &lt; 2 mg/dL and prothrombin time (PT) prolongation &lt; 3 seconds

          8. Will receive sorafenib therapy

          9. Life expectancy &gt; 3 months

         10. Will follow the pregnancy prevention protocol

        Exclusion Criteria:

          1. HCC is considered for curative therapy

          2. HCC with brain metastasis

          3. History of systemic therapy for HCC

          4. Indications for statin use, such as hyperlipidemia in cardiovascular diseases

          5. Any local treatment for HCC within 4 weeks

          6. Any active gastrointestinal bleeding within 4 weeks

          7. Liver transplant history or concomitant immunosuppressive therapy

          8. Concurrent any other malignancy

          9. Allergy to sorafenib or statins

         10. Pregnancy or lactation

         11. Serum AST or ALT &gt; 5x upper limit of normal

         12. Known HIV infection

         13. eGFR &lt; 30 ml/min

         14. Abnormal medical conditions that are unsuitable for study, such as uncontrolled
             hypertension, coronary arterial disease, or arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teng-Yu Lee, MD, PhD</last_name>
    <phone>423592525</phone>
    <phone_ext>3301</phone_ext>
    <email>tylee@vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teng-Yu Lee, PhD</last_name>
      <phone>4-23592525</phone>
      <phone_ext>3301</phone_ext>
      <email>tylee@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. 2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 3. Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172-179. 4. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516. 5. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45-54. 6. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942. 7. Wu J, Wong WW, Khosravi F, et al. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-6468. 8. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999;96:7797-7802. 9. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-1608. 10. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-630. 11. Chiu HF, Ho SC, Chen CC, et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106:894-898.</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Teng-Yu Lee</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

